OncoGenex Pharmaceuticals CEO John Bencich's 2022 pay slips 7% to $1.5M
OncoGenex Pharmaceuticals reports 2022 executive compensation
By ExecPay News
Published: April 28, 2023
OncoGenex Pharmaceuticals reported fiscal year 2022 executive compensation information on April 28, 2023.
In 2022, three executives at OncoGenex Pharmaceuticals received on average a compensation package of $1.3M, a 3% decrease compared to previous year.
Average pay of disclosed executives at OncoGenex Pharmaceuticals
John Bencich, Chief Executive Officer, received $1.5M in total, which decreased by 7% compared to 2021. 34% of Bencich's compensation, or $510K, was in salary. Bencich also received $223K in non-equity incentive plan, $359K in option awards, as well as $413K in stock awards.
Richard Stewart, Chairman, received a compensation package of $1.3M, which decreased by 5% compared to previous year. 32% of the compensation package, or $400K, was in salary.
Cindy Jacobs, Chief Medical Officer, earned $1.1M in 2022, a 5% increase compared to previous year.
Related executives
You may also like
Source: SEC filing on April 28, 2023.